Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short term Debt (2020 - 2023)

Zevra Therapeutics' Short term Debt history spans 3 years, with the latest figure at $37.7 million for Q4 2023.

  • For Q4 2023, Short term Debt changed N/A year-over-year to $37.7 million; the TTM value through Dec 2023 reached $37.7 million, changed N/A, while the annual FY2023 figure was $37.7 million, N/A changed from the prior year.
  • Short term Debt reached $37.7 million in Q4 2023 per ZVRA's latest filing, up from $683000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $37.7 million in Q4 2023 to a low of $390000.0 in Q4 2020.
  • Average Short term Debt over 3 years is $12.9 million, with a median of $683000.0 recorded in 2021.